03.26.2026
Latest News
Iktos announces a new partnership with Chemspeed to help pharmaceutical companies unlock new possibilities in automated chemical research
Iktos, a pioneer in artificial intelligence (AI) and robotics for drug discovery, today announced a collaboration with Chemspeed Technologies (a Bruker company), a Swiss leader in laboratory automation systems, to offer pharmaceutical partners a solution combining advanced synthesis planning and orchestration AI software with robotics for chemical synthesis execution. The partnership aims to help pharmaceutical companies accelerate discovery programs, increase laboratory productivity, and unlock new possibilities in automated chemical research.
Press releases and recognitions
Press articles
Drug discovery’s weakest link? Why synthesis is the critical bottleneck in the age of AI
In depth editorial article published by Innovations in Pharmaceutical Technology, introducing cluster synthesis as a major breakthrough enabling acceleration of small molecule discovery.
While artificial intelligence (AI) now accelerates molecular design at unprecedented speed, laboratory synthesis continues to lag behind, limiting the impact of digital innovation. Emerging frameworks such as AI-driven orchestration and cluster synthesis offer a path to reshape how laboratories align design with execution.
Press Contact
PR Agency
For any communication need please contact PRLab
Mail : dwain@prlab.co
Tel. : +31 202 443 748
